VRNA Insider Trading

Insider Ownership Percentage: 4.80%
Insider Buying (Last 12 Months): $188,928.00
Insider Selling (Last 12 Months): $9,819,879.28

Verona Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Verona Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal Insider BuyingTotal Insider Selling

Verona Pharma Share Price & Price History

Current Price: $57.24
Price Change: Price Increase of +2.41 (4.40%)
As of 01/30/2025 05:00 PM ET

This chart shows the closing price history over time for VRNA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$57.24Closing price on 01/30/25:

SEC Filings (Institutional Ownership Changes) for Verona Pharma (NASDAQ:VRNA)

85.88% of Verona Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VRNA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$13Mbought$11MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Verona Pharma logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More on Verona Pharma

Today's Range

Now: $57.24
Low: $54.63
High: $58.42

50 Day Range

MA: $45.17
Low: $38.01
High: $55.00

52 Week Range

Now: $57.24
Low: $11.39
High: $58.42

Volume

2,193,527 shs

Average Volume

1,611,627 shs

Market Capitalization

$4.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Who are the company insiders with the largest holdings of Verona Pharma?

Verona Pharma's top insider shareholders include:
  1. David Zaccardelli (CEO)
  2. Mark W Hahn (CFO)
  3. Orbimed Advisors Llc (Director)
  4. Kathleen A Rickard (Insider)
  5. Claire Poll (General Counsel)
  6. David R Ebsworth (Director)
  7. Martin Edwards (Director)
Learn More about top insider investors at Verona Pharma.

Who are the major institutional investors of Verona Pharma?

Verona Pharma's top institutional investors include:
  1. Jennison Associates LLC — 2.33%
  2. Hennion & Walsh Asset Management Inc. — 0.24%
  3. Moody Aldrich Partners LLC — 0.12%
  4. AMI Asset Management Corp — 0.05%
  5. PFG Investments LLC — 0.04%
  6. Diversify Wealth Management LLC — 0.03%
Learn More about top institutional investors of Verona Pharma stock.

Which major investors are selling Verona Pharma stock?

Within the previous quarter, VRNA stock was sold by these institutional investors:
  1. Moody Aldrich Partners LLC
  2. AMI Asset Management Corp
  3. Matisse Capital
  4. PFG Investments LLC
  5. Advisors Preferred LLC
Within the last year, company insiders that have sold Verona Pharma company stock include:
  1. David Zaccardelli (CEO)
  2. Mark W Hahn (CFO)
  3. Orbimed Advisors Llc (Director)
Learn More investors selling Verona Pharma stock.

Which major investors are buying Verona Pharma stock?

In the last quarter, VRNA stock was bought by institutional investors including:
  1. Jennison Associates LLC
  2. Hennion & Walsh Asset Management Inc.
  3. Legato Capital Management LLC
  4. Shilanski & Associates Inc.
  5. Values First Advisors Inc.
  6. Choreo LLC
  7. Diversify Wealth Management LLC
  8. EMC Capital Management
Within the last year, these company insiders have bought Verona Pharma stock:
  1. David Zaccardelli (CEO)
  2. Mark W Hahn (CFO)
Learn More investors buying Verona Pharma stock.